Novartis projects slowed growth, pins hopes on billions in pipeline potential
With Kisqali going off patent and decreasing prices impacting sales, Novartis has narrowed sales guidance to 5% growth. But management remains steadfast that they have a plan to get back on track.

What's Your Reaction?









